SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-13 |
| Reported value | $189,178,234 |
| Positions | 84 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Alphabet Inc-Cl C | GOOG | Common | $32,301,429 | 91,420 |
| Apollo Global Management, Inc. | APO | Common | $26,619,750 | 225,000 |
| Syndax Pharmaceutical, Inc. | SNDX | Common | $9,558,176 | 437,245 |
| Xeris Biopharma Holdings, Inc. | XERS | Common | $8,395,200 | 1,060,000 |
| Travere Therapeutics, Inc. | TVTX | Common | $8,367,090 | 147,282 |
| Protagonist Therapeutics, Inc | PTGX | Common | $7,722,540 | 63,000 |
| Bridgebio Pharma, Inc. | BBIO | Common | $6,915,468 | 92,850 |
| Iovance Biotherapeutics, Inc. | IOVA | Common | $6,656,000 | 1,600,000 |
| Alkermes PLC | ALKS | Common | $6,379,563 | 121,759 |
| JPMorgan Chase & Co. | JPM | Common | $5,924,018 | 18,098 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.